These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2514783)

  • 1. Cutaneous fibrinolytic potential, tPA dependent, is reduced in Behçet's disease.
    Lotti T; Matucci-Cerinic M
    Br J Dermatol; 1989 Dec; 121(6):713-6. PubMed ID: 2514783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defective fibrinolysis in Behçet's syndrome: significance and possible mechanisms.
    Aitchison R; Chu P; Cater DR; Harris RJ; Powell RJ
    Ann Rheum Dis; 1989 Jul; 48(7):590-3. PubMed ID: 2505697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation.
    Matucci-Cerinic M; Lotti T; Lombardi A; Pignone A; Iannone F; Beneforti E; Cinotti S; Morfini M; Caignoni M
    Int J Dermatol; 1990 Nov; 29(9):644-8. PubMed ID: 2125582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation and fibrinolytic activity in Behçet's disease.
    Hampton KK; Chamberlain MA; Menon DK; Davies JA
    Thromb Haemost; 1991 Sep; 66(3):292-4. PubMed ID: 1745999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the blood fibrinolytic enzyme system of patients with cutaneous vasculitis.
    Toki N; Yamura T
    Br J Dermatol; 1980 Jul; 103(1):41-50. PubMed ID: 6775670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Subclinical pro-thrombotic state in a relapse of Behcet's disease--case report].
    Undas A; Pinis G
    Pol Arch Med Wewn; 1996 Sep; 96(3):258-62. PubMed ID: 9122017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for an endothelial cell dysfunction in association with Behçet's disease.
    Schmitz-Huebner U; Knop J
    Thromb Res; 1984 May; 34(4):277-85. PubMed ID: 6429888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
    Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
    Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychogenic purpura with abnormally increased tPA dependent cutaneous fibrinolytic activity.
    Lotti T; Benci M; Sarti MG; Teofoli P; Senesi C; Bonan P; Ghersetich I; Panconesi E
    Int J Dermatol; 1993 Jul; 32(7):521-3. PubMed ID: 8340191
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
    Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
    J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the fibrinolytic system in Behçet's disease?
    Asbeck F; Meyer-Boernecke D; van de Loo J
    Haemostasis; 1977; 6(5):303-9. PubMed ID: 598751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator activity levels in patients with Behçet's syndrome.
    Mishima H; Masuda K; Shimada S; Toki N; Tsushima H; Gocho M
    Arch Ophthalmol; 1985 Jul; 103(7):935-6. PubMed ID: 4040357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Is Behçet's disease associated with characteristic abnormalities of coagulation and fibrinolysis? Apropos of 70 case reports].
    Conard J; Horellou MH; Wechsler B; Fassin D; Bletry O; Godeau P; Samama M
    J Mal Vasc; 1988; 13(3):257-61. PubMed ID: 3171405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factual or artificial inhibition of fibrinolysis and the occurrence of venous thrombosis in 3 cases of Behçet's disease.
    Kluft C; Michiels JJ; Wijngaards G
    Scand J Haematol; 1980 Nov; 25(5):423-30. PubMed ID: 6452679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue plasminogen activator release and plasminogen activator inhibitor levels in coronary artery disease.
    Meyers DG; Haire WD; Rasmussen JK; Boyd EJ
    Angiology; 1991 Jul; 42(7):561-7. PubMed ID: 1907440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fibrinolytic and peripheral serotonergic system in patients with glomerulonephritis].
    Małyszko J; Małyszko J; Myśliwiec M; Pawlak D; Buczko W
    Przegl Lek; 1995; 52(9):428-30. PubMed ID: 8834642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Parameters of hemostasis in Behçet's disease].
    Dupuy E; Tobelem G; Bourgeois P; Soria C; Pellerin A; Bellucci S; Caen JP
    Rev Med Interne; 1983 Dec; 4(4):317-21. PubMed ID: 6665348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis.
    Comerota AJ; Chouhan V; Harada RN; Sun L; Hosking J; Veermansunemi R; Comerota AJ; Schlappy D; Rao AK
    Ann Surg; 1997 Sep; 226(3):306-13; discussion 313-4. PubMed ID: 9339937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of bcl-2 protein in active skin lesions of Behçet's disease.
    Senturk N; Yildiz L; Sullu Y; Kandemir B; Turanli AY
    Int J Dermatol; 2001 Dec; 40(12):747-50. PubMed ID: 11903667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin.
    Espinosa G; Font J; Tàssies D; Vidaller A; Deulofeu R; López-Soto A; Cervera R; Ordinas A; Ingelmo M; Reverter JC
    Am J Med; 2002 Jan; 112(1):37-43. PubMed ID: 11812405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.